MA32429B1 - Modulateurs des canaux des ions calcium et leurs utilisations - Google Patents
Modulateurs des canaux des ions calcium et leurs utilisationsInfo
- Publication number
- MA32429B1 MA32429B1 MA33477A MA33477A MA32429B1 MA 32429 B1 MA32429 B1 MA 32429B1 MA 33477 A MA33477 A MA 33477A MA 33477 A MA33477 A MA 33477A MA 32429 B1 MA32429 B1 MA 32429B1
- Authority
- MA
- Morocco
- Prior art keywords
- alkyl
- represent
- hydrogen
- halogen
- dialkylamino
- Prior art date
Links
- 108090000312 Calcium Channels Proteins 0.000 title 1
- 102000003922 Calcium Channels Human genes 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 150000002431 hydrogen Chemical class 0.000 abstract 6
- -1 nitro , amino Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
L'invention concerne des composés de formule (1), des sels et des promédicaments, dans laquelle : r1, r2, r3 et r4 représentent hydrogène, alkyle, hydroxyalkyle, halogène, halogénoalkyle, alcoxy, halogénoalcoxy, alcoxycarbonyle, carboxyle, hydroxyle, nitro, amino, monoalkylamino, dialkylamino, acylamino, alcoxycarbonylamino, alkylsulfonyle, arylsulfonyle, alkylsulfonylamino, arylsulfonylamino, aminosulfonyle ou cyano, ou deux éléments quelconques parmi r1 à r4 qui sont adjacents sur le cycle peuvent représenter ensemble la fonction -o-(ch2)n-o-, dans laquelle n vaut de 1 à 3; r5 représente hydrogène ou alkyle; r6 représente hydrogène ou alkyle; et x est choisi dans le groupe constitué de : (a) les groupes de formule or7, r7 représentant l'hydrogène ou un alkyle qui est éventuellement substitué avec un substituant choisi parmi alkylsulfonylalkyle, hétérocycle saturé ou partiellement insaturé, alcoxy, carboxyle, nitro, amino, monalkylamino, dialkylamino, halogène et alcoxycarbonyle, à condition que lorsque r7 représente hydrogène ou éthyle, alors r1, r2, r3 et r4 ne puissent pas être choisis parmi hydrogène, halogène et alkyle; et (b) les groupes de formule nr8r9, r8 et r9 formant ensemble avec l'atome d'azote auquel ils sont attachés un groupe hétérocyclique saturé ou partiellement insaturé qui contient éventuellement au moins un hétéroatome supplémentaire choisi parmi les atomes d'azote, d'oxygène et de soufre, ledit groupe hétérocyclique saturé ou partiellement insaturé étant éventuellement également substitué par un ou plusieurs substituants choisis parmi alkyle, halogène, halogénoalkyle, alcoxy, alcoxycarbonyle, carboxyle, nitro, amino, monalkylamino, dialkylamino et hydroxyle, à condition que : (i) lorsque r8 + r9 + n = pipérazine, et r1 et/ou r2 et/ou r3 et/ou r4 représentent hydrogène, hydroxyle, nitro, amino, alkylamino, dialkylamino, alcoxycarbonylamino, halogène, alcoxy ou alkyle, alors l'atome d'azote à la position 4 de la pipérazine n'est pas substitué par un alkyle, (ii) lorsque r1, r2, r3, r4, r5 et r6 représentent chacun hydrogène, x ne représente pas pipérazinyle non substituée ou morpholino non substitué, (iii) lorsque r1, r2, r4, r5 et r6 représentent chacun hydrogène et que r3 représente hydrogène, brome ou hydroxyle, alors x ne représente pas méthoxy, (iv) lorsque r2 et r3 représentent chacun méthoxy ou qu'ils représentent ensemble -o-ch2-o- et que r1, r4, r5 et r6 représentent chacun hydrogène, x ne représente pas pipéridine non substituée. Les composés selon l'invention sont des bloquants du canal cavx et sont utilisés pour le traitement de divers troubles, y compris la douleur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0812192.3A GB0812192D0 (en) | 2008-07-03 | 2008-07-03 | Calcium ion channel modulators & uses thereof |
| PCT/GB2009/050787 WO2010001179A2 (fr) | 2008-07-03 | 2009-07-03 | Modulateurs des canaux des ions calcium et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32429B1 true MA32429B1 (fr) | 2011-06-01 |
Family
ID=39717915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33477A MA32429B1 (fr) | 2008-07-03 | 2010-12-31 | Modulateurs des canaux des ions calcium et leurs utilisations |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110166136A1 (fr) |
| EP (1) | EP2303840A2 (fr) |
| JP (1) | JP2011526618A (fr) |
| KR (1) | KR20110046460A (fr) |
| CN (1) | CN102143946A (fr) |
| AR (1) | AR072470A1 (fr) |
| AU (1) | AU2009265292A1 (fr) |
| BR (1) | BRPI0913970A2 (fr) |
| CA (1) | CA2729688A1 (fr) |
| CO (1) | CO6341611A2 (fr) |
| EA (1) | EA201170135A1 (fr) |
| GB (1) | GB0812192D0 (fr) |
| IL (1) | IL210224A0 (fr) |
| MA (1) | MA32429B1 (fr) |
| MX (1) | MX2010014455A (fr) |
| PE (1) | PE20110406A1 (fr) |
| TW (1) | TW201004942A (fr) |
| UY (1) | UY31959A (fr) |
| WO (1) | WO2010001179A2 (fr) |
| ZA (1) | ZA201100068B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105481851A (zh) * | 2014-09-19 | 2016-04-13 | 龚兆龙 | 六氢苯并萘啶类光学活性化合物及其药物用途 |
| EP3548888B1 (fr) | 2016-12-02 | 2023-04-05 | Sophion Bioscience A/S | Dispositif d'amélioration de joint d'étanchéité |
| WO2018100206A1 (fr) * | 2016-12-02 | 2018-06-07 | Sophion Bioscience A/S | Dispositif d'amélioration de joint d'étanchéité |
| CN115894330B (zh) * | 2022-09-06 | 2024-12-10 | 吉林医药学院 | 一种1-乙酰基-1h-吲哚-3-基乙酸酯衍生物的合成方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2825734A (en) * | 1955-04-11 | 1958-03-04 | Upjohn Co | Reduction of carbonylic radicals in indolyl-3 compounds |
| GB944443A (fr) * | 1959-09-25 | 1900-01-01 | ||
| US3217011A (en) * | 1965-05-07 | 1965-11-09 | Sterling Drug Inc | 1-(indolyglyoxalyl)-piperidines |
| GB9523999D0 (en) * | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
| US5756507A (en) * | 1995-12-14 | 1998-05-26 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19946301A1 (de) * | 1998-04-02 | 2001-04-19 | Asta Medica Ag | Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften |
| ATE430731T1 (de) * | 2002-12-10 | 2009-05-15 | Wyeth Corp | Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) |
| UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| DE60324183D1 (en) * | 2002-12-10 | 2008-11-27 | Wyeth Corp | Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) |
| JPWO2007040166A1 (ja) * | 2005-09-30 | 2009-04-16 | 大日本住友製薬株式会社 | 新規な縮合ピロール誘導体 |
| AU2006302371A1 (en) * | 2005-10-06 | 2007-04-19 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
| KR20080108407A (ko) * | 2006-02-27 | 2008-12-15 | 와이어쓰 | 근육 상태의 치료를 위한 ｐａｉ-1 억제제 |
| US7504399B2 (en) * | 2006-06-08 | 2009-03-17 | Bristol-Meyers Squibb Company | Piperazine enamines as antiviral agents |
-
2008
- 2008-07-03 GB GBGB0812192.3A patent/GB0812192D0/en not_active Ceased
-
2009
- 2009-07-02 TW TW098122395A patent/TW201004942A/zh unknown
- 2009-07-03 KR KR1020117002758A patent/KR20110046460A/ko not_active Withdrawn
- 2009-07-03 UY UY0001031959A patent/UY31959A/es not_active Application Discontinuation
- 2009-07-03 JP JP2011515635A patent/JP2011526618A/ja active Pending
- 2009-07-03 AR ARP090102503A patent/AR072470A1/es unknown
- 2009-07-03 EA EA201170135A patent/EA201170135A1/ru unknown
- 2009-07-03 US US13/002,374 patent/US20110166136A1/en not_active Abandoned
- 2009-07-03 AU AU2009265292A patent/AU2009265292A1/en not_active Abandoned
- 2009-07-03 EP EP09772859A patent/EP2303840A2/fr not_active Withdrawn
- 2009-07-03 PE PE2011000002A patent/PE20110406A1/es not_active Application Discontinuation
- 2009-07-03 CA CA2729688A patent/CA2729688A1/fr not_active Abandoned
- 2009-07-03 BR BRPI0913970A patent/BRPI0913970A2/pt not_active IP Right Cessation
- 2009-07-03 MX MX2010014455A patent/MX2010014455A/es not_active Application Discontinuation
- 2009-07-03 CN CN2009801345035A patent/CN102143946A/zh active Pending
- 2009-07-03 WO PCT/GB2009/050787 patent/WO2010001179A2/fr not_active Ceased
-
2010
- 2010-12-23 IL IL210224A patent/IL210224A0/en unknown
- 2010-12-30 CO CO10165100A patent/CO6341611A2/es not_active Application Discontinuation
- 2010-12-31 MA MA33477A patent/MA32429B1/fr unknown
-
2011
- 2011-01-03 ZA ZA2011/00068A patent/ZA201100068B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011526618A (ja) | 2011-10-13 |
| US20110166136A1 (en) | 2011-07-07 |
| AR072470A1 (es) | 2010-09-01 |
| WO2010001179A3 (fr) | 2010-11-11 |
| PE20110406A1 (es) | 2011-06-19 |
| TW201004942A (en) | 2010-02-01 |
| UY31959A (es) | 2010-01-05 |
| ZA201100068B (en) | 2012-06-27 |
| MX2010014455A (es) | 2011-04-11 |
| EP2303840A2 (fr) | 2011-04-06 |
| IL210224A0 (en) | 2011-03-31 |
| GB0812192D0 (en) | 2008-08-13 |
| CA2729688A1 (fr) | 2010-01-07 |
| CO6341611A2 (es) | 2011-11-21 |
| KR20110046460A (ko) | 2011-05-04 |
| AU2009265292A1 (en) | 2010-01-07 |
| BRPI0913970A2 (pt) | 2018-05-29 |
| EA201170135A1 (ru) | 2011-10-31 |
| WO2010001179A2 (fr) | 2010-01-07 |
| CN102143946A (zh) | 2011-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220247A1 (ar) | مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k | |
| TN2009000347A1 (fr) | Derives de pleuromutiline pour le traitement de maladies transmises par des microbes | |
| EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| MA31800B1 (fr) | Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| TNSN07178A1 (fr) | N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues | |
| AR025975A1 (es) | Compuestos quimicos. | |
| ATE353870T1 (de) | Dibenzylaminverbindung und deren medizinische verwendung | |
| MA33832B1 (fr) | Isoquinolinones et quinazolinones substituées | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| MA35364B1 (fr) | Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire | |
| MA26996A1 (fr) | Derives de glutaramide a substituant n-phenpropylcyclopentyle, servant d'inhibiteurs de nep pour un trouble d'eveil sexuel feminin | |
| MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
| MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
| DK0663912T3 (da) | Heterocykliske etherforbindelser til forstærkning af den kognitive funktion | |
| AR073348A1 (es) | Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1 | |
| CA2397636A1 (fr) | Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique | |
| MA30420B1 (fr) | Derives de terphenyle pour le traitment de la maladie d'alzheimer | |
| MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
| MA35184B1 (fr) | Antagonistes de trpv4 | |
| BRPI0513433A (pt) | derivados de hidantoìna para o tratamento de distúrbios inflamatórios | |
| MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
| TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| EA201000884A1 (ru) | Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз | |
| SA523451700B1 (ar) | (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان |